1,605 results match your criteria paronychia

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

Eur J Cancer 2021 Apr 2. Epub 2021 Apr 2.

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Giacomo Venezian 1, 20133, Milan, Italy.

Background: The treatment of metastatic non-small-cell lung cancer (mNSCLC) patients with EGFR/HER2 exon 20 insertion mutation (i-mut) remains an unmet clinical need. Poziotinib, a new generation tyrosine kinase inhibitor, is currently under investigation as a potential targeted therapy. This compassionate study of its use aims to describe the activity/toxicity of poziotinib in mNSCLC with EGFR/HER2-exon-20-i-mut. Read More

View Article and Full-Text PDF

Panitumumab-Induced Paronychia: A Case Report and a Brief Review of the Literature.

Skin Appendage Disord 2021 Feb 3;7(2):123-126. Epub 2020 Dec 3.

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Panitumumab is a recombinant, fully humanized IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab is indicated for patients with metastatic colorectal cancer with progressive refractory disease. Targeted therapies are well known to be well tolerated; however, they may induce toxicities that are distinct from those of classical chemotherapeutic agents. Read More

View Article and Full-Text PDF
February 2021

Chronic paronychia in cats with patellar fracture and dental anomaly syndrome.

J Feline Med Surg 2021 Mar 24:1098612X21998612. Epub 2021 Mar 24.

Langford Small Animal Hospital, Langford House, University of Bristol, Bristol, UK.

Case Series Summary: The aim of this case series was to describe the clinical features and treatment of paronychia in cats diagnosed with patellar fracture and dental anomaly syndrome (PADS). Clinical records, photographs, microbiology, cytology and histopathology reports were collected, and follow-up was obtained. Five cats with paronychia were included. Read More

View Article and Full-Text PDF

Bacterial and Viral Infections of the Nail Unit.

Dermatol Clin 2021 Apr 11;39(2):245-253. Epub 2021 Feb 11.

Department of Dermatology, Radboud University Medical Center, Rene Descartesdreef 1, Nijmegen 6525GL, The Netherlands.

Bacterial and viral infections of the nail unit are very common as primary infections, especially bacterial paronychia and warts, but they can also be superinfections complicating other nail disorders. In many nail unit infections, the clinical presentation is nonspecific: in these cases, diagnostic tests are mandatory before treatment, to avoid spread of the infection and drug resistance. The most common forms of bacterial and viral infections that may affect the nail unit are herein described in detail, with diagnostic and treatment options provided. Read More

View Article and Full-Text PDF

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Lung Cancer 2021 Apr 23;154:176-185. Epub 2021 Feb 23.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. Electronic address:

Objectives: To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing ARCHER 1050 trial.

Materials And Methods: In this ongoing, randomized, open-label, phase 3 trial (NCT01774721), eligible patients with newly diagnosed advanced EGFR mutation-positive NSCLC were randomized (1:1) to receive oral dacomitinib 45 mg/day or oral gefitinib 250 mg/day. Randomization, by a central computer system, was stratified by race and EGFR mutation type (exon 19 deletion mutation/exon 21 L858R substitution mutation). Read More

View Article and Full-Text PDF

Is lymphangitic streaking associated with different pathogens?

Am J Emerg Med 2021 Mar 1;46:34-37. Epub 2021 Mar 1.

Boston Children's Hospital, Department of Emergency Medicine, USA. Electronic address:

Objectives: Little is known regarding the differences in microbiology associated with cellulitis or abscess with or without lymphangitic streaking. The objective of our study is to assess whether there are differences in the pathogens identified from wound cultures of patients with paronychia with and without associated lymphangitis.

Methods: Retrospective cross-sectional study at a tertiary pediatric emergency department over 25 years. Read More

View Article and Full-Text PDF

Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.

Invest New Drugs 2021 Mar 13. Epub 2021 Mar 13.

Shanghai Henlius Biotech, Inc., Shanghai, China.

Purpose This study aimed to evaluate the safety and pharmacokinetic (PK) profiles of HLX07, a novel, recombinant, humanized anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced solid cancers who had failed standard therapy or for whom no standard therapy was available. Methods In this prospective, open-label, Phase I dose escalation study, patients aged ≥18 years (≥20 years for patients in Taiwan) with histologically-confirmed metastatic or recurrent epithelial carcinoma that had no K-RAS or B-RAF mutations were enrolled in a '3 + 3' escalation design. HLX07 was administered weekly by 2-h intravenous infusion at doses ranging from 50 to 800 mg. Read More

View Article and Full-Text PDF

Chronic paronychia as a manifestation of skin leishmaniasis.

Rev Soc Bras Med Trop 2021;54. Epub 2021 Mar 8.

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, AM, Brasil.

View Article and Full-Text PDF

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors.

Front Pharmacol 2021 18;12:636324. Epub 2021 Feb 18.

Phase I Clinical Trial Unit, The First Hospital of Jilin University, Jilin, China.

The presented phase I, first-in-human study evaluated the tolerance, pharmacokinetics, and preliminary efficacy of larotinib mesylate in patients with advanced solid tumors. Cancer patients were assigned to receive larotinib mesylate at 50-400 mg dose levels until disease progression or intolerance. Dose-limiting toxicities were assessed during Cycles 0 and 1. Read More

View Article and Full-Text PDF
February 2021

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.

BMC Cancer 2021 Mar 1;21(1):208. Epub 2021 Mar 1.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 113-8603 1-1-5 Sendagi Bunkyo-Ku, Tokyo, Japan.

Background: Lung cancer is most common among older individuals. However, polypharmacy and comorbidities, which are also more common in older individuals, can limit treatment options. Previous studies suggest that afatinib can be used safely and effectively in elderly patients. Read More

View Article and Full-Text PDF

Chronic paronychia and nail dystrophy: an atypical presentation of allergic contact dermatitis to garlic.

Int J Dermatol 2021 Feb 11. Epub 2021 Feb 11.

Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India.

View Article and Full-Text PDF
February 2021

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).

Transl Lung Cancer Res 2021 Jan;10(1):252-260

Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Background: Afatinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor () mutations. Many patients treated with afatinib experience skin or gastrointestinal toxicity. However, an effective management strategy has not been established. Read More

View Article and Full-Text PDF
January 2021

Atypical paronychia: don't forget herpesvirus.

Dermatol Online J 2021 Jan 15;27(1). Epub 2021 Jan 15.

Department of Internal Medicine, Groupe Hospitalier de la Haute-Saône, Vesoul.

Paronychia is usually caused by bacterial infections. Herpetic whitlow is an acute infection of the fingers or toes caused by herpes simplex viruses and it typically presents with vesicles. We report the case of a 78-year-old woman with gingivostomatitis and atypical paronychia in several fingers without blisters. Read More

View Article and Full-Text PDF
January 2021

[Successful treatment with silver nitrate chemical cauterization for paronychia and granulation in a patient with chronic lymphocytic leukemia undergoing ibrutinib therapy].

Rinsho Ketsueki 2021 ;62(1):35-41

National Cancer Center Hospital East, Department of Hematology and Oncology.

A 72-year-old man with leukocytosis, anemia, and lymphadenopathy was diagnosed with chronic lymphocytic leukemia (CLL) in August 2017 and was carefully monitored in a "watch-and-wait" manner until it became an "active disease." Ibrutinib (IBR) was initiated orally in July 2018 at a dose of 420 mg/day after disease progression due to chromosome 17p deletion (del 17p). The patient showed partial response after transient lymphocytosis while on IBR treatment. Read More

View Article and Full-Text PDF
February 2021

Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change.

BMC Pediatr 2021 Feb 6;21(1):67. Epub 2021 Feb 6.

Department of Pediatrics, Institute for Maternal and Child Health Burlo Garofolo, Trieste, Italy.

Background: Plexiform neurofibromas (PNs) are congenital tumors that affect around 50 % of the subjects with neurofibromatosis type 1. Despite being histologically benign, PNs can grow rapidly, especially in the pediatric age, and cause severe morbidities. In the past, various therapeutic approaches have been proposed to treat these masses, none of which obtained valuable results. Read More

View Article and Full-Text PDF
February 2021

The role of topical timolol in wound healing and the treatment of vascular lesions: A narrative review.

Dermatol Ther 2021 Mar 13;34(2):e14847. Epub 2021 Feb 13.

Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Beta-2 adrenergic receptors are the only subgroup of beta-adrenergic receptors expressed in the membrane of large cells, including skin keratinocytes, fibroblasts, and melanocytes. Alterations in the function or concentration of β2 adrenoreceptors related to keratinocytes are associated with some skin conditions. Some findings suggest the role of β2 adrenoreceptors in maintaining the function and integrity of the epidermis. Read More

View Article and Full-Text PDF

Metastasis to the finger of oral floor squamous cell carcinoma: A case report.

Clin Case Rep 2021 Jan 1;9(1):8-11. Epub 2020 Dec 1.

First Department of Oral and Maxillofacial Surgery Graduate School of Dentistry Osaka University Suita Japan.

When cetuximab is used, diagnosing finger metastasis can be difficult due to the side effects of paronychia and color changes of nails. Finger metastasis may be a marker of multiple metastasis; therefore, it can lead to a poor prognosis. Read More

View Article and Full-Text PDF
January 2021

Reliability of capillary refill time for evaluation of tissue perfusion in simulated vascular occluded limbs.

Eur J Trauma Emerg Surg 2021 Jan 21. Epub 2021 Jan 21.

Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Purpose: No standardized execution or evidence demonstrates the area of the digit giving the most accurate capillary refill time (CRT). This study investigated the reliability and validity of CRT, and the relative merits of areas where the test could be performed.

Methods: In all, 127 healthy volunteers were assessed for normal CRT at the fingernail, lateral paronychia, and proximal and distal pulps of the index finger. Read More

View Article and Full-Text PDF
January 2021

Nail unit squamous cell carcinoma: updates on diagnosis, surgical approach, and the use of mohs micrographic surgery.

Mohammed Dany

Cutis 2020 Nov;106(5):E11-E14

Department of Dermatology, University of Pennsylvania, Philadelphia, USA.

Nail unit squamous cell carcinoma (NSCC) is a malignant neoplasm that can arise from any part of the nail unit including the nail bed, nail matrix, nail groove, and nail fold. Nail unit SCC is the most common malignant nail neoplasm, and yet its diagnosis often is delayed, partly due to the clinical presentation of NSCC mimicking benign conditions such as onychomycosis, warts, and paronychia. Nail unit SCC has a low rate of metastasis; however, a delayed diagnosis often can result in local destruction and bone invasion. Read More

View Article and Full-Text PDF
November 2020

New findings associated with presumptive systemic lupus erythematosus in a kitten.

JFMS Open Rep 2020 Jul-Dec;6(2):2055116920979271. Epub 2020 Dec 21.

Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montréal, Saint-Hyacinthe, QC, Canada.

Case Summary: An 8-month-old neutered male domestic shorthair kitten was examined for anorexia, lethargy and palatine ulcers. Systemic lupus erythematosus (SLE) was suspected based on a positive antinuclear antibody (ANA) titer and six manifestations of autoimmunity: fever, paronychia, oral ulcers, proteinuria, thrombocytopenia and leukopenia. Mastocytemia was observed on the blood smear. Read More

View Article and Full-Text PDF
December 2020

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.

Int J Clin Oncol 2021 Apr 1;26(4):701-707. Epub 2021 Jan 1.

Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.

Background: The triplet-agent (5-fluorouracil/leucovorin, oxaliplatin, and irinotecan; FOLFOXIRI) combined with an anti-epidermal growth factor receptor antibody as a first-line treatment of metastatic colorectal cancer (mCRC) has shown promising results in Western trials. This phase Ib study assessed the safety of FOLFOXIRI plus cetuximab in Japanese patients with RAS wild-type mCRC.

Methods: Patients with previously untreated RAS wild-type mCRC received weekly cetuximab (400 mg/m at week 1 and subsequently 250 mg/m) plus FOLFOXIRI that consisted of irinotecan (100, 120, and 150 mg/m defined as dose levels 0, 1, and 2), followed by oxaliplatin 85 mg/m and l-leucovorin 200 mg/m and then 5-fluorouracil 2400 mg/m. Read More

View Article and Full-Text PDF

Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children.

Pediatr Dermatol 2020 Dec 27. Epub 2020 Dec 27.

Department of Dermatology Hospital Sant Joan de Deu, Barcelona, Spain.

Background: Mitogen-activated protein kinase inhibitors (MEKi) are currently used for the treatment of central nervous system tumors in children and have shown promising results. Cutaneous adverse effects are among the most common toxicities described in adults, but few studies exist in pediatric patients.

Objective: We aimed to describe the cutaneous adverse effects associated with MEKi in pediatric patients. Read More

View Article and Full-Text PDF
December 2020

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.

PLoS One 2020 21;15(12):e0243997. Epub 2020 Dec 21.

Institut Sainte-Catherine, Avignon, France.

Background: Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC.

Patients And Methods: PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials. Read More

View Article and Full-Text PDF
February 2021

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Drugs 2021 Feb;81(2):257-266

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou, Guangdong, 510080, China.

Background: ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) and an EGFR-activating mutation, reported significant improvement in overall survival (OS) with dacomitinib.

Objective: This paper reports an updated OS analysis of ARCHER 1050 after an extended follow-up.

Patients And Methods: In this multinational, multicenter trial, adults (aged ≥ 18 years or ≥ 20 years in Japan and Korea) with newly diagnosed NSCLC and EGFR mutation (exon 19 deletion or exon 21 L858R substitution), and no history of central nervous system metastases, were randomized 1:1 to receive dacomitinib 45 mg/day (n = 227) or gefitinib 250 mg/day (n = 225). Read More

View Article and Full-Text PDF
February 2021

Topical brimonidine for pyogenic granuloma after paronychia surgery.

JAAD Case Rep 2021 Jan 9;7:41-43. Epub 2020 Nov 9.

Department of Dermatovenereology, Sichuan University West China Hospital, Chengdu, China.

View Article and Full-Text PDF
January 2021

A Rare Paronychia with Superinfection with and : The Importance of Early Microbiological Diagnosis.

Pathogens 2020 Nov 29;9(12). Epub 2020 Nov 29.

Departamento de Podología, Universidad de Sevilla, 41009 Sevilla, Spain.

is an anaerobic, gram-negative bacillus which naturally thrives in the human vagina, and is usually related to vaginal tract infections. However, this microorganism can also cause infections in other body locations. Infections with are frequently severe due to the risk of osteomyelitis and the lack of good protocols for adequate therapeutic management. Read More

View Article and Full-Text PDF
November 2020

Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report.

Yonago Acta Med 2020 Nov 24;63(4):379-384. Epub 2020 Nov 24.

Division of Otolaryngology, Head and Neck Surgery, Department of Sensory and Motor Organs, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.

Cetuximab is an effective drug used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma. Skin toxicities such as paronychia and skin exsiccation are common adverse events caused by cetuximab. Skin toxicities may cause significant physical and psychosocial discomfort. Read More

View Article and Full-Text PDF
November 2020

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa125. Epub 2020 Sep 24.

The Legacy Heritage Oncology Center and Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva, Israel.

Background: Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood-brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when it is used as a first line of therapy compared with gefitinib and erlotinib. It is also efficient as second-line therapy for patients who developed the T790M resistance mutation following treatment with previous generation TKIs. Here, we report 11 patients who were treated by an increasing dose of osimertinib from 80 mg to 160 mg QD orally following intracranial progression in either first- or second-line setting. Read More

View Article and Full-Text PDF
September 2020